

HEALTH ECONOMICS AND OUTCOMES RESEARCH STRATEGY

FELLOWSHIP PROGRAM

ABBVIE - UNIVERSITY OF WASHINGTON
2027-2029

W UNIVERSITY *of* WASHINGTON



ABOUT ABBVIE

AbbVie's mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives

Treating
74M+
people annually

in more than
180+
countries

across
30+
brands

Treating
75+
conditions

Value & Evidence

V&E Purpose

In Value & Evidence, we bring our unique expertise to shape end-to-end evidence strategy, execution, and communication to:

- Empower better healthcare decisions
- Accelerate access to medications
- Maximize value for patients worldwide



V&E Pillars

HEOR Strategy

Provide strategic global leadership in identifying, conducting & delivering innovative health economics & outcomes evidence generation solutions across product lifecycles.

- Patient Centered Outcomes Research
- Global Value Assessment Center of Expertise
- RWE Center of Expertise
- Value & Access (US)
- Evidence Planning & Execution

Therapeutic Areas

Aesthetics

Immunology

Oncology

Neuroscience

Eye Care & Specialty

ABOUT THE UNIVERSITY OF WASHINGTON

The University of Washington is a world-class leader in health sciences education and has been consistently listed in US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly noted for its strong research programs and since 1974 has received more federal funds for research and training than any other public university in the United States. It fosters a highly collegial atmosphere between departments and academic units, creating a particularly attractive environment for such partnerships between the public and private sectors.

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute is housed within the University of Washington School of Pharmacy, which boasts nearly 125 years of academic and research success. Faculty in the program (1) provide advanced research training for graduate students, postdoctoral fellows and clinicians (PharmDs, MDs), (2) conduct rigorous scientific research in economic evaluations and outcomes of pharmaceuticals and other health technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with the goal of improving patient care.

The CHOICE Institute faculty participating in the fellowship have been chosen both for their dedication to teaching and their excellence in research. Each is trained either as a health economist or health services researcher and all have an extensive history of effective economic evaluations and pharmacoepidemiologic research.



ABOUT OUR FELLOWSHIP

The University of Washington/AbbVie HEOR Fellowship is a two-year program that provides training and hands-on experience in a broad-range of health economics and outcomes research topics. The program is structured to allow fellows to gain proficiency in health outcomes strategy and research as conducted in both academic and pharmaceutical industry settings.

Fellowship Directors



Kyu Lee

University of Washington

*PhD, MS,
Endowed Assistant
Professor of Health Decision
Sciences*

E-Mail:
kyueunl@uw.edu



Jae Lee

AbbVie

*PharmD, MS,
Associate Director,
HEOR Strategy*

E-Mail:
jaehyun.lee@abbvie.com

The Fellowship Program

- The University of Washington and AbbVie are pleased to offer one, 2-year HEOR Fellowship position for the academic year 2027-2029. The fellow will spend their first year at the University of Washington (Seattle, WA), and the second year at AbbVie (Mettawa, IL; Irvine, CA; or Florham Park, NJ).
- Compensation includes tuition, a competitive stipend, medical insurance, conference attendance, relocation package, and holiday/vacation time. A Master's (MS) Degree in Health Economics & Outcomes Research is awarded upon completion of all course requirements and thesis project.

FELLOWSHIP STRUCTURE



First Year Objectives



Learn principles of economics and in particular how economics influence the use, cost, and availability of pharmaceuticals



Understand the complexity behind drug policy and how it determines relationships between consumers, health care providers, insurers, payers, and government agencies



Appreciate the breadth and scope of analytical methods needed for the assessment of Patient Reported Outcomes (PROs), economic modeling, and real-world studies



Gain insight of formulary development, maintenance and evaluation in institutional, managed care, and state-level government programs

Second Year Objectives



Apply principles of economic evaluations, outcomes research and real-world analysis in a pharmaceutical environment with hands-on research and collaborations



Integrate into cross-functional and HEOR work streams to develop a deeper understanding of the role of HEOR in drug development and commercialization



Develop key research tactics and innovate to drive the field of HEOR forward and maximize value demonstration of AbbVie products

PERSPECTIVES FROM PAST AND CURRENT FELLOWS

Insights from current AbbVie colleagues



2018-2022

Jamie Ta

“The MS program at CHOICE, together with the multiple opportunities I had to lead high-impact HEOR studies, collaborate with cross-functional partners, and support HEOR strategy... helped me gain a better understanding of the role of HEOR in the pharmaceutical industry and develop the technical, leadership, and communication skills that have prepared me well for my current role.”



2019-2021

Jae Lee

“The goal of our program is to equip our fellows with the training and skills necessary to succeed in HEOR. Over half our past fellows have stayed on with the company following their fellowship and this speaks to the quality of our program and our fellows.”



2020-2022

TJ Park

“Completing the UW/AbbVie HEOR fellowship was a very rewarding experience. The academic and industry mentors are all incredibly supportive and the cross-company fellow cohort brings a sense of community.”



2021-2023

Gina Ahmadyar

“The most memorable experience for me was the moment I completed the analysis for my thesis. It was an incredible feeling to take it from an idea and culminate it into tangible results.”



2021-2023

Annaliza Dominguez

“The knowledge and skillset gained in my first year paired with the experience of managing a variety of projects in my second year, including RWE and PRO validation studies, have set me up for success and helped build confidence going into my post-fellowship role.”



2022-2024

Jae Kim

“The incredible support from all the mentors made the 1st year fellowship experience truly great. The knowledge and experience I gained in the first year of the fellowship prepared me well to manage projects in my second year at AbbVie.”



2022-2024

Zach Baldwin

“The fellowship program was a great mixture of didactic education and practical experience. It was from this fellowship that I was able to interact with cross-functional colleagues, led critical projects for my manager, and gained necessary exposure to best prepare myself to be a strong contributor as an HEOR Strategy team member.”



2023-2025

Richard Ta

“Equipped with a solid HEOR foundation from the first year, I am now eagerly prepared to contribute to the value story of life-changing products through evidence generation.”



2023-2025

Filmon Haile

“The breadth and depth of HEOR education that I received in the first year was invaluable, and it really showed in my second year when I was integrated into the team.”



2025-2027

Andrew Cotterill

“The standout from my interview was how relaxed and conversational it felt. The panel was very candid and left me feeling that there would be a supportive team invested in helping me reach my goals.”



2025-2027

Janice Jang

“During my interview, I found the team to be very welcoming and genuinely interested in my experiences and interests. I left with the impression that I would be well supported in pursuing my goals.”



2026-2028

Sharon Kim

“What stood out most was how the interview felt so welcoming and personal, allowing me to connect naturally with the team. Their genuine interest in my goals gave me confidence that I would be supported and encouraged to grow throughout the fellowship.”

First Year Fellow

Sharon Kim
PharmD



Sharon recently graduated from the University of California, Irvine, with her PharmD. During pharmacy school, she developed an interest in HEOR through elective courses. This interest deepened during her HEOR externship, where she conducted a targeted literature review to inform evidence-generation strategy and reviewed a retrospective real-world claims analysis.

Sharon is excited to begin her journey as a postdoctoral fellow and collaborate closely with faculty at CHOICE and her AbbVie advisors. During the fellowship, she hopes to build a strong foundation in HEOR methods and apply her training to generate evidence that supports meaningful healthcare decisions. For her systematic literature review, she will synthesize real-world evidence on the impact of socioeconomic and sociodemographic factors on outcomes among patients with small cell lung cancer. She also looks forward to further developing her interests in real-world evidence and exploring a related topic for her thesis.

Second Year Fellows

Andrew Cotterill
PharmD, MS



Andrew earned his PharmD from Nova Southeastern University, where his interest in health economics and outcomes research (HEOR) was sparked through pharmacoepidemiology research examining gaps in secondary prophylaxis among myocardial infarction patients. During the first year of his fellowship, Andrew collaborated with Drs. Noémi Kreif and Kyueun Lee on research quantifying healthcare resource utilization and costs among patients with essential tremor. In his second year, Andrew supports the Therapeutic Neurotoxins HEOR Strategy team across a range of projects while continuing to expand his expertise in HEOR methods and strategic evidence generation.

ABSTRACTS FROM FELLOWSHIP

- Cotterill A, Kreif N. Determining an Economically Justifiable Price for Trontinemab in Early Alzheimer's Disease. ISPOR – The Professional Society for Health Economics and Outcomes Research Annual Meeting. May 2026, Philadelphia, PA.
- Cotterill A, Kreif N. Economic Burden of Essential Tremor: A Systematic Review. UW Corporate Advisory Board, September 2025, Seattle, WA.

MANUSCRIPT FROM FELLOWSHIP

- Cotterill A, Kreif N, Lee K. Healthcare Resource Utilization and Costs Among Patients with Essential Tremor. (In Progress)

Janice Jang
PharmD, MS



Janice received her PharmD from the University of Arizona. She developed an interest in HEOR through diverse research experiences, including her PharmD summer research internship. In the first year of her fellowship, Janice examined the healthcare resource utilization and expenditures of patients with inflammatory bowel disease (IBD) who switched or cycled after anti-tumor necrosis factor therapy. In her second year of her fellowship, Janice is helping to support the HEOR strategy for risankizumab in its indication for psoriasis and strengthening her collaborative research skills through a number of research projects.

ABSTRACTS FROM FELLOWSHIP

- Jang J, Lee K. Cost-effectiveness of remibrutinib for moderate to severe chronic spontaneous urticaria in the U.S. ISPOR 2026, May 2026, Philadelphia, PA.
- Jang J, Sharma D, Lee K. Criteria Used to Identify Suboptimal Therapy in Patients with Inflammatory Bowel Disease: Systematic Review. UW Corporate Advisory Board, September 2025, Seattle, WA.

MANUSCRIPT FROM FELLOWSHIP

- Jang J, Kreif N, Lee K. Healthcare Utilization and Cost Burden with Switching or Cycling After Starting Anti-tumor Necrosis Factors in Inflammatory Bowel Disease: A Retrospective Cohort Analysis. (In Progress)

PAST FELLOWS

FILMON HAILE PharmD, MS 2023-2025

Manager, Health Economics and Outcomes Research at AbbVie

KEY RESEARCH FROM FELLOWSHIP



1. F. Haile, C. English, and K. Lee, "Psychotropic Prescribing Patterns Among Bipolar-I Patients Prior to Established Bipolar-I Disorder Diagnosis," *Bipolar Disorders* 28, no. 5 (2026): e70137, <https://doi.org/10.1111/bdi.70137>.

RICHARD TA PharmD, MS 2023-2025

Senior Manager, Health Economics and Outcomes Research at AbbVie

KEY RESEARCH FROM FELLOWSHIP



1. Ta R, Lee K, Li J. Associations between Use of Targeted Therapies, Hospitalizations and Emergency Department Visits Among Patients with Atopic Dermatitis: A Retrospective Cohort Study

ZACH BALDWIN PharmD, MS 2022-2024

Associate Director, Health Economics and Outcomes Research at AbbVie

KEY RESEARCH FROM FELLOWSHIP



1. Baldwin Z, Yan C, Agapova M, Devine B. Impact of Carbidopa-Levodopa Enteral Suspension Initiation on Oral Medication Treatment Patterns in Persons with Parkinson's Disease: A Retrospective Cohort Analysis.

JAE ROK KIM, PharmD, MS 2022-2024

Senior Manager, Health Economics and Outcomes Research at AbbVie

KEY RESEARCH FROM FELLOWSHIP



1. Kim J, Park TJ, Devine B, Agapova M, Blumenfeld A, Smith J, Shah D. Healthcare Resource Utilization and Costs Associated with the Misdiagnosis of Migraine.

ANNALIZA DOMINGUEZ PharmD, MS 2021-2023

Senior Manager, Health Economics and Outcomes Research at AbbVie

KEY RESEARCH FROM FELLOWSHIP



1. Dominguez A, Liang Y, Abbed T, Mukhatyar V, Shimoga S. Real-world Use of AlloDerm Accellular Dermal Matrix in Head and Neck Procedures in the United States.

GINA AHMADYAR PharmD, MS 2021-2023

Senior Manager, Health Economics and Outcomes Research at AbbVie

KEY RESEARCH FROM FELLOWSHIP



1. Ahmadyar G, Hansen R. Ocular Injectable Treatment Options for Post-Cataract Macular Edema: A Systematic Review of Current Literature. *J Cataract Refract Surg*. 2022 Feb 10. doi: 10.1097/j.jcrs. 0000000000000908. Epubahead of print. PMID: 35171142.
2. Ahmadyar G, Carlson JJ, Kimura A *et al*. Real-world treatment patterns and economic burden of post-cataract macular edema. *BMC Ophthalmol*. 2023;23(1):380. doi.org/10.1186/s12886-023-03113-x

TAE JIN PARK PharmD, MS 2020-2022

Director, Health Economics and Outcomes Research at AbbVie

KEY RESEARCH FROM FELLOWSHIP



1. Park TJ, Hansen R, Gillard P, Shah D, Ferguson WG, Piccini J, Romano MA, Devine B. Healthcare resource utilization and costs for patients with postoperative atrial fibrillation in the United States. *J Med Econ*. 2023 Jan-Dec;26(1):1417-1423.

JAE HYUN LEE PharmD, MS 2019-2021

Associate Director, Health Economics and Outcomes Research at AbbVie

KEY RESEARCH FROM FELLOWSHIP



1. Lee J, Shewale A, Barthold D, Devine B. Geographic Variation in the Use of Triptans and Opioids for the Acute Treatment of Migraine Attacks. *Headache: The Journal of Head and Face Pain*. 2021 Nov;61(10):1499-1510.

JAMIE TA PharmD, MS 2018-2020

Associate Director, US Market Access Pipeline at AbbVie

KEY RESEARCH FROM FELLOWSHIP



1. Ta JT, Sullivan SD, Tung A, Oliveri D, Gillard P, Devine B. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. *J Manag Care Spec Pharm*. 2021 Feb;27(2):223-39.

APPLICATION ELIGIBILITY

- Applicants for this fellowship must have a degree in pharmacy by Spring 2027 and have some research experience (preference will be given to those with a high academic standing).
- Excellent written and verbal communication skills are also essential.
- Applicants will be required to submit their:

- 1 Curriculum vitae
- 2 Letter describing their career goals
- 3 Three letters of recommendations

- Selection of fellows will be made by a steering committee composed of the University of Washington faculty members and representatives from AbbVie.



APPLICATION DEADLINE

October 19th, 2026

APPLICATION INFORMATION

Interested students must apply through the University of Washington Graduate School Site. The online application process can be found at:

[UW-AbbVie HEOR Fellowship Application Process](#)

Fellowship Information Session

September 21st 2026

5:00 PM — 6:00 PM PST

Registration required: [UW-AbbVie 2026 Registration](#)

ABBVIE FELLOWSHIP PROGRAMS

University Location	Seattle, WA
AbbVie Location	Mettawa, IL; Irvine, CA; or Florham Park, NJ
Program Length	2 years
Programs Offered	Health Economics and Outcomes Research
Eligibility	Degree in Pharmacy

CONTACT INFORMATION

If you have any questions, please contact:

University of Washington

Marina Gano, M.Ed

Graduate Program & Operations Manager

1959 N E Pacific St. Suite H375,

Box 357630 Seattle, WA 98195

E-Mail: mcgano@uw.edu

Phone: 206- 616-1383

AbbVie

Jae Lee, PharmD, MS

Associate Director, HEOR Strategy

2525 Dupont Drive,

Irvine, CA 92612

Email: jaehyun.lee@abbvie.com

Phone: 949-431-8658